MedMen Enterprises Inc. Logo

MedMen Enterprises Inc.

MMEN.CN

(0.8)
Stock Price

0,02 CAD

-38.42% ROA

-46.51% ROE

-0.23x PER

Market Cap.

12.187.743,53 CAD

309.9% DER

0% Yield

-76.65% NPM

MedMen Enterprises Inc. Stock Analysis

MedMen Enterprises Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

MedMen Enterprises Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0.2x) suggests it's undervalued, making it an attractive opportunity for investors.

2 Graham Number

The company's Graham number indicates that it is undervalued compared to its stock price, suggesting a potentially favorable investment opportunity.

3 ROE

Negative ROE (-46.51%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

4 ROA

The stock's ROA (-38.42%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

5 DER

The stock is burdened with a heavy load of debt (310%), making it financially unstable and potentially risky for investors.

6 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

7 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

MedMen Enterprises Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

MedMen Enterprises Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Hold

MedMen Enterprises Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

MedMen Enterprises Inc. Revenue
Year Revenue Growth
2000 305.464
2001 0 0%
2002 30.105 100%
2003 19.341 -55.65%
2004 20.278 4.62%
2005 22.176 8.56%
2006 36.415 39.1%
2007 33.599 -8.38%
2008 18.141 -85.22%
2009 27.656 34.41%
2010 19.656 -40.7%
2011 24.924 21.13%
2012 20.644 -20.73%
2013 26.652 22.54%
2014 20.066 -32.82%
2016 2.671.812 99.25%
2017 39.783.102 93.28%
2018 129.963.405 69.39%
2019 157.112.281 17.28%
2020 145.065.771 -8.3%
2021 140.811.689 -3.02%
2022 108.898.680 -29.31%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

MedMen Enterprises Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2000 0
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

MedMen Enterprises Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2000 0
2001 0 0%
2002 45.594 100%
2003 19.113 -138.54%
2004 9.366 -104.07%
2005 8.913 -5.09%
2006 11.109 19.78%
2007 41.730 73.38%
2008 41.691 -0.1%
2009 28.223 -47.72%
2010 53.703 47.45%
2011 236.992 77.34%
2012 133.035 -78.14%
2013 240.605 44.71%
2014 136.184 -76.68%
2016 14.138.166 99.04%
2017 98.180.978 85.6%
2018 234.649.949 58.16%
2019 200.273.872 -17.16%
2020 124.585.936 -60.75%
2021 108.724.757 -14.59%
2022 63.841.804 -70.3%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

MedMen Enterprises Inc. EBITDA
Year EBITDA Growth
2000 -269.547
2001 -74.816 -260.28%
2002 -24.707 -202.83%
2003 -7.554 -227.1%
2004 219.043 103.45%
2005 2.448 -8847.83%
2006 15.949 84.65%
2007 -18.446 186.46%
2008 -32.882 43.9%
2009 -11.264 -191.91%
2010 -43.071 73.85%
2011 -219.850 80.41%
2012 -120.348 -82.68%
2013 -221.609 45.69%
2014 -124.006 -78.71%
2016 -13.221.387 99.06%
2017 -91.449.994 85.54%
2018 -198.751.834 53.99%
2019 -149.039.214 -33.36%
2020 -54.842.800 -171.76%
2021 -35.562.775 -54.21%
2022 -27.767.920 -28.07%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

MedMen Enterprises Inc. Gross Profit
Year Gross Profit Growth
2000 -89.558
2001 0 0%
2002 10.808 100%
2003 11.559 6.51%
2004 12.084 4.34%
2005 11.361 -6.36%
2006 27.058 58.02%
2007 23.284 -16.21%
2008 8.809 -164.35%
2009 16.959 48.06%
2010 10.631 -59.52%
2011 17.142 37.98%
2012 12.687 -35.11%
2013 18.996 33.21%
2014 12.178 -55.98%
2016 868.135 98.6%
2017 13.850.225 93.73%
2018 60.877.707 77.25%
2019 58.120.974 -4.74%
2020 67.289.170 13.63%
2021 69.727.458 3.5%
2022 52.590.528 -32.59%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

MedMen Enterprises Inc. Net Profit
Year Net Profit Growth
2000 -1.271.660
2001 -75.182 -1591.46%
2002 325.431 123.1%
2003 -24.718 1416.62%
2004 189.272 113.06%
2005 -28.930 754.24%
2006 -21.050 -37.44%
2007 -48.884 56.94%
2008 -68.809 28.96%
2009 -46.230 -48.84%
2010 -78.480 41.09%
2011 -249.923 68.6%
2012 -122.803 -103.51%
2013 -228.136 46.17%
2014 -124.141 -83.77%
2016 -15.418.308 99.19%
2017 -66.647.221 76.87%
2018 -277.046.611 75.94%
2019 -475.749.370 41.77%
2020 -145.445.431 -227.1%
2021 -165.554.955 12.15%
2022 -124.833.304 -32.62%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

MedMen Enterprises Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2000 -29
2001 -2 -2700%
2002 7 116.67%
2003 -1 0%
2004 4 100%
2005 -1 0%
2006 0 0%
2007 -1 100%
2008 -2 0%
2009 -1 0%
2010 -2 0%
2011 -1 0%
2012 -1 0%
2013 -1 0%
2014 0 0%
2016 -26 100%
2017 -2 -2500%
2018 -3 50%
2019 -2 -100%
2020 0 0%
2021 0 0%
2022 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

MedMen Enterprises Inc. Free Cashflow
Year Free Cashflow Growth
2000 -86.158
2001 0 0%
2002 -13.328 100%
2003 -12.495 -6.66%
2004 -24.611 49.23%
2005 17.583 239.97%
2006 13.612 -29.17%
2007 -14.905 191.32%
2008 -64.352 76.84%
2009 -14.307 -349.79%
2010 -22.626 36.76%
2011 -106.077 78.67%
2012 -143.547 26.1%
2013 -87.857 -63.39%
2014 -106.950 17.85%
2016 -28.377.310 99.62%
2017 -128.466.184 77.91%
2018 -364.152.889 64.72%
2019 -170.955.296 -113.01%
2020 -67.474.027 -153.36%
2021 -72.185.897 6.53%
2022 -13.000.836 -455.24%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

MedMen Enterprises Inc. Operating Cashflow
Year Operating Cashflow Growth
2000 -86.158
2001 0 0%
2002 -3.249 100%
2003 -12.495 74.01%
2004 -24.611 49.23%
2005 17.583 239.97%
2006 13.612 -29.17%
2007 -14.905 191.32%
2008 -64.352 76.84%
2009 -14.307 -349.79%
2010 -22.626 36.76%
2011 -106.077 78.67%
2012 -143.547 26.1%
2013 -87.857 -63.39%
2014 -106.950 17.85%
2016 -18.152.351 99.41%
2017 -68.876.515 73.65%
2018 -236.099.863 70.83%
2019 -110.126.749 -114.39%
2020 -59.700.010 -84.47%
2021 -62.529.441 4.52%
2022 -14.838.878 -321.39%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

MedMen Enterprises Inc. Capital Expenditure
Year Capital Expenditure Growth
2000 0
2001 0 0%
2002 10.079 100%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2016 10.224.959 100%
2017 59.589.669 82.84%
2018 128.053.026 53.46%
2019 60.828.547 -110.51%
2020 7.774.017 -682.46%
2021 9.656.456 19.49%
2022 -1.838.042 625.37%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

MedMen Enterprises Inc. Equity
Year Equity Growth
2000 -767.127
2001 -856.123 10.4%
2002 -685.627 -24.87%
2003 -767.811 10.7%
2004 -601.794 -27.59%
2005 -662.906 9.22%
2006 -803.441 17.49%
2007 -685.854 -17.14%
2008 -829.945 17.36%
2009 -927.044 10.47%
2010 -273.445 -239.02%
2011 -413.349 33.85%
2012 -1.899 -21666.61%
2013 361.215 100.53%
2014 191.455 -88.67%
2016 33.579.865 99.43%
2017 197.197.285 82.97%
2018 200.849.266 1.82%
2019 -176.888.450 213.55%
2020 -253.633.619 30.26%
2021 -318.512.736 20.37%
2022 -357.388.431 10.88%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

MedMen Enterprises Inc. Assets
Year Assets Growth
2000 0
2001 2.870 100%
2002 883 -225.03%
2003 3.002 70.59%
2004 3.602 16.63%
2005 2.235 -61.12%
2006 2.769 19.26%
2007 16.748 83.47%
2008 12.066 -38.81%
2009 7.296 -65.39%
2010 780.269 99.07%
2011 29.063 -2584.84%
2012 37.034 21.53%
2013 372.187 90.05%
2014 200.633 -85.51%
2016 60.431.402 99.67%
2017 282.190.342 78.58%
2018 634.630.235 55.53%
2019 574.263.604 -10.51%
2020 472.463.690 -21.55%
2021 323.223.684 -46.17%
2022 215.587.114 -49.93%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

MedMen Enterprises Inc. Liabilities
Year Liabilities Growth
2000 767.127
2001 858.994 10.69%
2002 686.511 -25.12%
2003 770.813 10.94%
2004 605.395 -27.32%
2005 665.141 8.98%
2006 806.209 17.5%
2007 702.602 -14.75%
2008 842.011 16.56%
2009 934.339 9.88%
2010 1.053.715 11.33%
2011 442.411 -138.18%
2012 38.934 -1036.34%
2013 10.973 -254.84%
2014 9.178 -19.56%
2016 26.851.537 99.97%
2017 84.993.057 68.41%
2018 433.780.969 80.41%
2019 751.152.054 42.25%
2020 726.097.309 -3.45%
2021 641.736.420 -13.15%
2022 572.975.545 -12%

MedMen Enterprises Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.06
Net Income per Share
-0.05
Price to Earning Ratio
-0.23x
Price To Sales Ratio
0.14x
POCF Ratio
-0.65
PFCF Ratio
-0.45
Price to Book Ratio
0.12
EV to Sales
4.42
EV Over EBITDA
-49.55
EV to Operating CashFlow
-16.56
EV to FreeCashFlow
-14.04
Earnings Yield
-4.43
FreeCashFlow Yield
-2.24
Market Cap
0,01 Bil.
Enterprise Value
0,38 Bil.
Graham Number
0.32
Graham NetNet
-0.41

Income Statement Metrics

Net Income per Share
-0.05
Income Quality
0.33
ROE
-0.47
Return On Assets
-0.31
Return On Capital Employed
0.07
Net Income per EBT
0.97
EBT Per Ebit
3.7
Ebit per Revenue
-0.21
Effective Tax Rate
0.03

Margins

Sales, General, & Administrative to Revenue
0.56
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0.05
Gross Profit Margin
0.5
Operating Profit Margin
-0.21
Pretax Profit Margin
-0.79
Net Profit Margin
-0.77

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.02
Free CashFlow per Share
-0.02
Capex to Operating CashFlow
0.18
Capex to Revenue
-0.05
Capex to Depreciation
-0.39
Return on Invested Capital
-0.03
Return on Tangible Assets
-0.38
Days Sales Outstanding
16.24
Days Payables Outstanding
161.66
Days of Inventory on Hand
122.33
Receivables Turnover
22.48
Payables Turnover
2.26
Inventory Turnover
2.98
Capex per Share
-0

Balance Sheet

Cash per Share
0,01
Book Value per Share
0,09
Tangible Book Value per Share
-0.3
Shareholders Equity per Share
0.09
Interest Debt per Share
0.31
Debt to Equity
3.1
Debt to Assets
1.76
Net Debt to EBITDA
-47.98
Current Ratio
0.19
Tangible Asset Value
-0,40 Bil.
Net Current Asset Value
-0,48 Bil.
Invested Capital
3.1
Working Capital
-0,38 Bil.
Intangibles to Total Assets
0.2
Average Receivables
0,01 Bil.
Average Payables
0,02 Bil.
Average Inventory
14171949.5
Debt to Market Cap
31.11

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

MedMen Enterprises Inc. Dividends
Year Dividends Growth

MedMen Enterprises Inc. Profile

About MedMen Enterprises Inc.

MedMen Enterprises Inc., together with its subsidiaries, operates as a cannabis retailer in the United States. The company provides products under the MedMen Red and LuxLyte brand names. As of June 25, 2022, it operated 19 stores in California, Nevada, Illinois, Arizona, and Massachusetts. MedMen Enterprises Inc. is based in Los Angeles, California.

CEO
Mr. Amit Pandey
Employee
428
Address
8740 S Sepulveda Boulevard
Los Angeles, 90045

MedMen Enterprises Inc. Executives & BODs

MedMen Enterprises Inc. Executives & BODs
# Name Age
1 Kimble Cannon
General Counsel & Corporate Secretary
70
2 Richard Ormond
Chief Restructuring Officer
70
3 Karen Torres
Chief Supply Chain Officer
70
4 Mr. Amit Pandey
Chief Financial Officer
70
5 Ms. Stéphanie Van Hassel
Vice President of Investor Relations
70

MedMen Enterprises Inc. Competitors